Some examples of long-term side effects you may experience from Ozempic include pancreatitis, vision problems, acute kidney injury, and acute gallbladder disease
Among the 58% of adults who say they want to lose weight, nearly one-third (32%) expect to start a prescription GLP-1 drug in 2026, which translates to an estimated 48 million American adults including 9% who say they definitely will and 23% who say they probably will
Sometimes, savings cards or manufacturer coupons can help lower the price, but out-of-pocket costs can still be different for each drug
As importantly, GLP-1 driven improvements in morbidity and mortality across so many conditions and patient populations strongly impacts the overall risk-reward calculation for prescribers considering a GLP-1 for a patient with SUD
Key Takeaway The Medicare GLP-1 Bridge program begins July 1, 2026, giving eligible Part D beneficiaries early access to Wegovy, Foundayo, and Zepbound KwikPen before full Part D weight-loss coverage arrives January 1, 2027